This study is a prospective, multicenter, observational study on metastatic, operable colorectal cancer to evaluate the proof of concept of the cfDNA analysis for the early detection of recurrences
Study Type
OBSERVATIONAL
Enrollment
141
detection of tumor DNA alteration in cf-DNA
Fondazione del Piemonte per l' Oncologia - IRCCS Candiolo
Candiolo, Torino, Italy
RECRUITINGOspedale Mauriziano
Torino, Italy
NOT_YET_RECRUITINGrelapse rate in MRD+ patients
Percentage of patients with MRD (minimal residual disease) with documented relapse. MRD is defined as detection, through liquid biopsy, of any of the molecular alterations evaluated in any plasma sample drawn within 40 days from surgery.
Time frame: immediately surgery and up to 2 years after surgery
relapse rate in MRD- patients
Percentage of patients with no MRD (minimal residual disease) with documented relapse. MRD- is defined as detection, through liquid biopsy, of no molecular alterations evaluated in any plasma sample drawn within 40 days from surgery.
Time frame: immediately surgery and up to 2 years after surgery
minimal residual disease detection rate
percentage of patients with detectable MRD (minimal residual disease) defined as detection, through liquid biopsy, of any of the molecular alterations evaluated in any plasma sample drawn within 40 days from surgery.
Time frame: up to 40 days after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.